{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "BIOA",
  "name": "BioAge Labs, Inc.",
  "url": "https://orbyd.app/dossiers/BIOA/",
  "json_url": "https://orbyd.app/dossiers/BIOA.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Statin-for-inflammation leg broke on someone else's Phase 3: Novo's ZEUS missed MACE at HR 0.99 on 2026-07-31 despite lowering hsCRP, and BIOA fell 59.6% intraday. QUELL-CV's primary endpoint is hsCRP — the exact surrogate ZEUS just discredited — and topline is guided only to \"2H 2026\". Narrative failed, $18 IPO shelf lost by gap, no base yet at $11.72.",
  "invalidation_trigger": "A weekly close below $10 loses the 2026-07-31 ZEUS gap-down zone and puts the pre-pivot $4 range back in scope; secondarily, a QUELL-CV topline landing in 2H 2026 as an hsCRP-only win, with no partner and no outlined cardiovascular outcomes trial, resolves the binary without reviving the narrative.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Single-asset clinical-stage issuer: no product revenue. The $2.4M Q2 2026 revenue line is legacy collaboration income, not product sales.",
    "QUELL-CV's primary endpoint is a biomarker — percent change in hsCRP over 12 weeks — not a cardiovascular outcome.",
    "Prior lead asset azelaprag was discontinued in December 2024 (Phase 2 STRIDES) on hepatic transaminase elevations, months after the September 2024 IPO at $18.",
    "Cash, equivalents and marketable securities $381.3M at 2026-06-30 with runway guided through 2029; 45.8M shares outstanding vs 37.4M at 2025-12-31.",
    "Company guides trial timing only to half-years ('2H 2026' for QUELL-CV topline); no fixed data date is published in advance.",
    "Next scheduled reporting checkpoint is the Q3 2026 10-Q, expected early-to-mid November 2026."
  ],
  "body_markdown": "## Current Thesis\nThe statin-for-inflammation leg that carried BIOA from $4.07 to a $25.96 intraday high in early July did not break on BioAge's own data. On 2026-07-31 Novo Nordisk reported that ZEUS — a Phase 3 of the IL-6 ligand inhibitor ziltivekimab in more than 6,300 patients with ASCVD, chronic kidney disease and elevated inflammation — missed on major adverse cardiovascular events, hazard ratio 0.99 (95% CI 0.88–1.11), while delivering the expected reductions in free IL-6 and hsCRP. Shares fell 59.6% in that morning's trade (Investing.com, 2026-07-31) and closed 2026-08-07 at $11.72, 53.3% under the $25.1 adjusted 52-week high, RSI(14) 28.8, three-month return -34.9%.\n\nThe damage is specific rather than atmospheric. QUELL-CV, the Phase 2 that was supposed to be the re-rating event, has as its primary endpoint percent change from baseline in hsCRP over 12 weeks — the same biomarker ziltivekimab suppressed on its way to a null outcome. Topline is guided only to \"2H 2026\" (reaffirmed in the 2026-08-05 Q2 update), so nothing resolves on a known date.\n\n**Life-cycle: DEAD.** Dated 2026-07-31 — the narrative premise (lower hsCRP → fewer cardiovascular events → statin-scale franchise) took a direct hit from a completed outcomes trial, and the structure went with it: the June breakout shelf near the $18 September-2024 IPO price was lost in one session by gap. What remains is a cash-heavy single-asset option with a discredited surrogate endpoint, not the story that was being bought in June and July.\n\n## Bull Case\n- **Mechanistic distinction is arguable.** NLRP3 sits upstream of IL-1β; CANTOS (canakinumab, direct IL-1β blockade) reduced MACE, while ZEUS blocked IL-6, one node downstream. *Inference, not measurement:* the read-through from ZEUS to an NLRP3 inhibitor is contestable, and the full ZEUS dataset had not been presented as of 2026-08-05.\n- **Phase 1 pharmacology is deep.** BGE-102 delivered median 86% hsCRP reduction and up to 98% IL-1β suppression (December 2025 topline, restated in the 2026-08-05 Q2 business update).\n- **Balance sheet is not the constraint.** $381.3M in cash, cash equivalents and marketable securities at 2026-06-30, runway guided through 2029, against a Q2 net loss of $26.1M. No forced financing on the near calendar.\n- **Q2 print beat on both lines (2026-08-05).** EPS $(0.58) vs $(0.60) consensus; revenue $2.451M vs $1.920M consensus (collaboration revenue $2.4M, flat year-over-year).\n- **Sell-side has cut targets without cutting ratings.** BTIG reiterated Buy with a $40 target on 2026-08-03 and again 2026-08-06; Needham maintained Buy and lowered its target to $35 on 2026-07-31.\n- **Two legs that do not depend on the CV-outcome premise.** QUELL-DME, a Phase 1b/2a of BGE-102 in diabetic macular edema, initiation guided mid-2026 with data mid-2027; a separate APJ agonist IND targeted by year-end 2026.\n- **What a buyer gets has shifted toward the balance sheet.** $381.3M cash at 2026-06-30 against 45.8M shares outstanding and an $11.72 close on 2026-08-07 — the non-cash component of the equity has compressed hard (inference from those figures).\n\n## Bear Case\n- **The surrogate is the endpoint.** QUELL-CV randomises roughly 160 adults with obesity and elevated inflammation to 30/60/90 mg once-daily BGE-102 or placebo and grades percent change in hsCRP over 12 weeks. After 2026-07-31, an hsCRP win carries less information about events than it did on 2026-07-30.\n- **ZEUS was not a dosing or engagement failure.** Novo Nordisk stated ziltivekimab produced the expected drops in free IL-6 and hsCRP; the hazard ratio was 0.99 across >6,300 patients on contemporary background therapy. Measured result: in that population, lowering the marker did not lower the event rate.\n- **Company-specific safety precedent.** Azelaprag's STRIDES Phase 2 was discontinued in December 2024 on hepatic transaminase elevations, months after the September 2024 IPO at $18. BGE-102 is brain-penetrant, adding a CNS exposure surface to the hepatic one.\n- **No revenue engine.** Collaboration revenue $2.4M in Q2 2026 against a $26.1M net loss, widened from $21.6M in Q2 2025.\n- **Equity was issued into the re-rating.** 45.8M shares outstanding at 2026-06-30 versus 37.4M at 2025-12-31, following the upsized $132.3M follow-on. That count is now measured against a price 53% below the 52-week high.\n- **A CV outcomes programme is not funded.** Runway through 2029 covers QUELL-CV, QUELL-DME and an IND; a MACE-powered outcomes trial is a different order of capital (inference).\n- **Target dispersion is wide and unresolved.** Jefferies lowered its target to $21 after the Novo miss on 2026-07-31; BTIG sits at $40. Both against an $11.72 close.\n\n## Setup & Price Structure\n- **Basis:** $11.72 close on 2026-08-07. 52-week high $25.1 (adjusted), -53.3%; 52-week low $4.07 (an intraday $4.11 was quoted by Investing.com on 2026-07-31). RSI(14) 28.8. Three-month return -34.9%.\n- **The prior structural line resolved by gap.** The level flagged in the 2026-07-12 note — a weekly close below $18, the June shelf sitting on the IPO price — was taken out inside the 2026-07-31 session, with no opportunity to trade the level. The $18 zone is now overhead supply.\n- **No base has formed.** Price sits above the 2026-07-31 gap-down zone near $10 and beneath every meaningful rising average; a handful of post-crash sessions is too short a sample to call a bottom.\n- **Positioning observables, stated as observables:** the Q2 print is already behind the tape (2026-08-05), so no imminent earnings date compresses the range; the next hard company event is undated (\"2H 2026\"); four of the eight headlines in the last 30 days are same-day 2026-07-31 movers screens, so recent attention was event-driven rather than accumulation-driven; analyst targets span $21 to $40 while the close is $11.72; the share count rose 8.4M in six months.\n- **What the tape has not yet done:** reclaimed the $18 shelf, or lost the gap-down zone. Both remain open questions.\n\n## Catalyst Calendar (next 30 days)\n\n- **No confirmed dated company catalyst between 2026-08-08 and 2026-09-07.** Q2 results were released 2026-08-05; BTIG's reiterations landed 2026-08-03 and 2026-08-06.\n- **~2026-08-31 (est.):** QUELL-DME Phase 1b/2a initiation. Still described as \"planned to initiate in mid-2026\" in the 2026-08-05 update, so an initiation release could land inside the window or slip past it.\n- **2H 2026 (undated company guide):** QUELL-CV topline, ~160 patients, primary endpoint percent change in hsCRP over 12 weeks.\n- **~2026-11-10 (est.):** Q3 2026 10-Q and business update — the next scheduled checkpoint on QUELL-CV enrolment and DME timing.\n- **~2026-12-31 (company guide):** first IND filing for the APJ agonist programme.\n\n## Elapsed catalysts\n\n- **TBD 2026 (undated):** presentation of the full ZEUS dataset at a scientific meeting. Novo Nordisk indicated on 2026-07-31 that detailed results follow; the subgroup and responder detail is what resolves the read-through argument. *(passed 9d ago)*\n\n## What Would Change Our Mind\nThe structure that defined the bull leg is already gone — the $18 IPO/June shelf was lost by gap on 2026-07-31 — so the live question is whether a second, different leg forms rather than whether the first one rolled over. Three observables would rebuild a constructive case: the full ZEUS dataset showing MACE separation among the deepest hsCRP responders, which would localise the failure to the IL-6 node; a QUELL-CV topline that pairs Phase 1-scale hsCRP knockdown with movement in cardiometabolic measures beyond CRP; and QUELL-DME dosing its first patient, which would put a non-cardiovascular readout on the calendar for mid-2027.\n\nConfirming the bear read instead: a weekly close below $10 loses the 2026-07-31 gap-down zone and puts the pre-pivot $4 range back in scope. Secondarily, a QUELL-CV topline arriving in 2H 2026 as an hsCRP-only win — no partner, no outlined outcomes trial, no funding path for one — resolves the binary without restoring the narrative. Any transaminase elevation or neuropsychiatric adverse-event disclosure in QUELL-CV would end the thesis outright, given the azelaprag precedent from December 2024.\n\n## Correlation Notes\n- **BIOA is currently priced off third-party data.** The single largest move in the name's history was set by Novo Nordisk's 2026-07-31 release, not by a BioAge disclosure. Any further ziltivekimab data — Novo continues the drug in HERMES and ARTEMIS per its own congress materials — is a read-through event for this equity.\n- **The anti-inflammatory basket moved together.** Monte Rosa Therapeutics (GLUE) suffered its worst session in years on the same 2026-07-31 news (Yahoo Finance/Benzinga coverage, 2026-07-31), which is the shape of a pathway repricing rather than a company-specific event.\n- **Obesity-complex adjacency persists.** QUELL-CV enrols adults with obesity and elevated inflammation, and the company's pre-pivot asset was an oral APJ agonist dosed alongside tirzepatide, so sentiment in the cardiometabolic complex still colours the story.\n- **With no dated company catalyst until QUELL-CV, drift is dominated by biotech risk appetite** across a 45.8M-share count and by whatever the next inflammation-CV dataset from any sponsor shows.",
  "first_seen": "2026-06-23",
  "last_analyzed": "2026-08-08T14:23:58+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}